36. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, et al. (1997) Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3: 1823–1829. 37. Broceno C, Wilkie S, Mittnacht S (2002) RB activation defect in tumor cell lines. Proc Natl Acad Sci U S A 99: 14200–14205. 38. Dou QP, An B, Will PL (1995) Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci U S A 92: 9019–9023. 39. Hitomi M, Yang K, Stacey AW, Stacey DW (2008) Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression. Mol Cell Biol 28: 5478–5493. 40. Choo DW, Baek HJ, Motoyama N, Cho KH, Kim HS, et al. (2009) ATM is required for rapid degradation of cyclin D1 in response to gamma-irradiation. Biochem Biophys Res Commun 378: 847–850. 41. Di Leonardo A, Linke SP, Clarkin K, Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540–2551. 42. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704. 43. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707. 44. Hall M, Bates S, Peters G (1995) Evidence for different modes of action of cyclin- dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11: 1581–1588. 45. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825. 46. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, et al. (1999) Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein- mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A 96: 1002–1007. 47. Gu J, Xia X, Yan P, Liu H, Podust VN, et al. (2004) Cell cycle-dependent regulation of a human DNA helicase that localizes in DNA damage foci. Mol Biol Cell 15: 3320–3332. 48. Zhou BB, Bartek J (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4: 216–225. 49. Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, et al. (2006) Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 119: 2784–2794. 50. Petersen L, Hasvold G, Lukas J, Bartek J, Syljuasen RG (2010) p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors. Cell Prolif 43: 365–371. 51. Warmerdam DO, Kanaar R (2010) Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat Res 704: 2–11. 52. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, et al. (2009) The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895–1909. 53. Claudio PP, Tonini T, Giordano A (2002) The retinoblastoma family: twins or distant cousins? Genome Biol 3: reviews3012. 54. Stewart ZA, Pietenpol JA (2001) p53 Signaling and cell cycle checkpoints. Chem Res Toxicol 14: 243–263. 55. Zhang X, Succi J, Feng Z, Prithivirajsingh S, Story MD, et al. (2004) Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Mol Cell Biol 24: 9207–9220. 56. Knudsen ES, Sexton CR, Mayhew CN (2006) Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Curr Mol Med 6: 749–757. 57. Abe Y, Matsumoto S, Wei S, Nezu K, Miyoshi A, et al. (2001) Cloning and characterization of a p53-related protein kinase expressed in interleukin-2- activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J Biol Chem 276: 44003–44011. 58. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164–171. 59. Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, et al. A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. Cancer Res 70: 6325–6335. 60. Lin Y, Khokhlatchev A, Figeys D, Avruch J (2002) Death-associated protein 4 binds MST1 and augments MST1-induced apoptosis. J Biol Chem 277: 47991–48001. 61. Glantschnig H, Rodan GA, Reszka AA (2002) Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J Biol Chem 277: 42987–42996. Mechanism of G1 Radiation Checkpoint Activation 62. Graves JD, Draves KE, Gotoh Y, Krebs EG, Clark EA (2001) Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis. J Biol Chem 276: 14909–14915. 63. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, et al. (2001) Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 21: 2743–2754. 64. Fuchs SY, Adler V, Pincus MR, Ronai Z (1998) MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A 95: 10541–10546. 65. Lafarga V, Cuadrado A, Lopez de Silanes I, Bengoechea R, Fernandez- Capetillo O, et al. (2009) p38 Mitogen-activated protein kinase- and HuR- dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol Cell Biol 29: 4341–4351. 66. Densham RM, O’Neill E, Munro J, Konig I, Anderson K, et al. (2009) MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol Cell Biol 29: 6380–6390. 67. Chehab NH, Malikzay A, Appel M, Halazonetis TD (2000) Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14: 278–288. 68. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14: 289–300. 69. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, et al. (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287: 1824–1827. 70. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, et al. (1992) Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71: 323–334. 71. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, et al. (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118: 493–504. 72. Ludlow JW, Howell RL, Smith HC (1993) Hypoxic stress induces reversible hypophosphorylation of pRB and reduction in cyclin A abundance independent of cell cycle progression. Oncogene 8: 331–339. 73. Fasanaro P, Magenta A, Zaccagnini G, Cicchillitti L, Fucile S, et al. (2006) Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress. Faseb J 20: 1242–1244. 74. Tomida A, Suzuki H, Kim HD, Tsuruo T (1996) Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells. Oncogene 13: 2699–2705. 75. Casanovas O, Miro F, Estanyol JM, Itarte E, Agell N, et al. (2000) Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem 275: 35091–35097. 76. Veech RL (2003) A humble hexose monophosphate pathway metabolite regulates short- and long-term control of lipogenesis. Proc Natl Acad Sci U S A 100: 5578–5580. 77. Kalia VK, Prabhakara S, Narayanan V (2009) Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy. J Cancer Res Ther 5 Suppl 1: S57–60. 78. Tschoep K, Conery AR, Litovchick L, DeCaprio JA, Settleman J, et al. (2011) A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev 25: 814–830. 79. Niida H, Nakanishi M (2006) DNA damage checkpoints in mammals. Mutagenesis 21: 3–9. 80. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB (2009) Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 8: 3112–3119. 81. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622–629. 82. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67–73. 83. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835–848. 84. Swanton C, Nicke B, Marani M, Kelly G, Downward J (2007) Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs. Cell Cycle 6: 2001–2004. PLoS ONE | www.plosone.org 14 February 2012 | Volume 7 | Issue 2 | e31627